menu search

Biovie says blinded data points to hopeful alzheimer's treatment potential

BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston suggests its ...

October 25, 2023, 2:19 pm

Takeda: why i'm staying bearish on this generic drug dividend play

High yields may seem attractive, however, homework can go a long way. Takeda's Phase 3 ADMIRE CD II study & Phase 3 EXCLAIM-2 trial both failed to mee...

October 24, 2023, 2:43 pm

Soleno (slno) soars as prader-willi syndrome study meets goal

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and second...

September 27, 2023, 9:01 am

Merck (mrk), eisai combo therapy fail two lung cancer studies

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung...

September 25, 2023, 1:32 pm

Travere (tvtx) slumps 41% on mixed results from igan drug study

Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely ...

September 22, 2023, 1:31 pm

Why shares of travere therapeutics are slumping thursday

Travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of its en...

September 21, 2023, 12:57 pm

Why is crinetics pharmaceuticals (crnx) stock up 64% today?

Crinetics Pharmaceuticals (NASDAQ: CRNX ) stock is on the rise Monday after the company announced positive clinical trial results. According to a pre...

September 11, 2023, 8:04 am

Crinetics pharmaceuticals shares surge 65%, analysts raise price target after acromegaly treatment results

Shares of Crinetics Pharmaceuticals Inc. CRNX, -1.18% gained 65% premarket on Monday after the company announced positive results from a late-stage st...

September 11, 2023, 8:01 am

Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 pathfndr-1 study evaluating treatment of patients with acromegaly

83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an I...

September 10, 2023, 2:00 pm

Okyo pharma completes enrollment in phase 2 clinical trial to treat dry eye disease

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has completed full enrollment of patients in the randomized portion of the Phase 2 multi-center, doubl...

September 8, 2023, 8:35 am

Alnylam's (alny) zilebesiran meets goals in mid-stage study

Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key seconda...

September 8, 2023, 8:17 am

Fibrogen stock plummets as muscular dystrophy drug trial fails

FibroGen Inc (NASDAQ:FGEN) plummeted some 27% lower in Wednesday's early deals after revealing that its intended treatment for Duchenne muscular dystr...

August 30, 2023, 9:39 am

Fibrogen shares fall after failure in late-stage study of duchenne muscular dystrophy treatment

Shares of FibroGen Inc. FGEN, +3.23% fell 23% premarket on Wednesday after the company said its investigational treatment for Duchenne muscular dystro...

August 30, 2023, 7:55 am

Praxis precision medicines to present analyses of patient-focused, clinically meaningful endpoints from essential1 study of ulixacaltamide in essential tremor at the 2023 mds international congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating gene...

August 28, 2023, 7:00 am

Sensiml to present technical session at silicon labs' works with conference

Company's CTO to Share Insights on TinyML Solutions PORTLAND, Ore. , Aug. 21, 2023 /PRNewswire/ -- SensiML Corporation, a leading developer of AI tool...

August 21, 2023, 7:52 pm

Merck's (mrk) welireg meets renal cell carcinoma study goals

Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual ...

August 21, 2023, 3:02 pm

Exelixis' (exel) prostate cancer study meets primary endpoint

Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints i...

August 21, 2023, 12:47 pm

Applied therapeutics: buy for upcoming pre-nda meeting (i expect a positive outcome)

Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in d...

August 17, 2023, 4:28 am

Quoin pharmaceuticals provides corporate update and announces second quarter 2023 financial results

Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study Subject’s skin was asses...

August 2, 2023, 8:45 pm

Kodiak sciences discontinues development of eye disorder therapeutic; shares plummet

Kodiak Sciences shares fell by more than 45% after the biopharmaceutical company announced that it was discontinuing its tarcocimab program for eye di...

July 24, 2023, 1:59 pm


Search within

Pages Search Results: